90 results
6-K
EX-99.1
BPTSY
Biophytis S.A.
30 Sep 24
Interim Financial Report
5:00pm
, the Board of Directors comprises four members, two of whom are independent:
Stanislas Veillet, Chairman and CEO,
Mrs. Nadine Coulm (independent)
Mr … . Claude Allary (independent)
Mr. Jean Mariani
2.1.5 Stock markets
On April 24, 2024, the Company announced that it had received notice from
6-K
EX-99.1
BPTSY
Biophytis S.A.
1 Jul 24
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
12:10pm
, particularly in elderly patients with co-morbidities, that is independent of the SARS-COV2 strain."
The poster presented at the Congress, which details
6-K
EX-99.1
ba2ac
8 Mar 24
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy
11:20am
6-K
EX-99.1
sgrdoth7
28 Sep 23
Current report (foreign)
10:18am
6-K
EX-99.1
efgll7tcbt pox
27 Sep 23
Half-year Financial Report
5:00pm
F-1
EX-23.1
n0zmb iwfa1apz
4 Aug 23
Registration statement (foreign)
4:18pm
F-1
j7cd3
4 Aug 23
Registration statement (foreign)
4:18pm
F-1
EX-23.2
1acs2f2vyy05mcaehs
4 Aug 23
Registration statement (foreign)
4:18pm
6-K
EX-10.2
q6wnwqn
21 Jul 23
Biophytis Announces $3.8 Million
6:01am
6-K
EX-10.3
03vlcughmyd
21 Jul 23
Biophytis Announces $3.8 Million
6:01am
6-K
EX-10.4
zcl 1jje4matdd
21 Jul 23
Biophytis Announces $3.8 Million
6:01am
424B5
fp9yyup4
20 Jul 23
Prospectus supplement for primary offering
5:27pm
20-F/A
fn953p0h2jlviqwmw1g
3 Jul 23
Annual report (foreign) (amended)
4:15pm
F-3
EX-4.6
oyi7frjcs
21 Apr 23
Shelf registration (foreign)
4:16pm
F-3
EX-23.2
y3l8rbf42im
21 Apr 23
Shelf registration (foreign)
4:16pm
F-3
20mebtxofq
21 Apr 23
Shelf registration (foreign)
4:16pm
F-3
EX-23.1
r8o181962ts8kth1
21 Apr 23
Shelf registration (foreign)
4:16pm